[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599397":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":75,"collaborators":20,"id":77,"slug":20,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":20,"eligibilityCriteria":82,"healthyVolunteers":78,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":20,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":20,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Ouro Medicines","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"OM336 Dose Escalation","EXPERIMENTAL","Participants will receive OM336 via subcutaneous injection in ascending dose cohorts",[13],"Drug: OM336",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","OM336","OM336 is an engineered bispecific antibody directed against BCMA and CD3",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Study Sponsor","CONTACT","415-429-4887","info@ouromeds.com",[28,47,61],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"The Canberra Hospital","RECRUITING","Canberra","Australian Capital Territory","2605","Australia","AU",{"type":37,"coordinates":38},"Point",[39,40],149.12807,-35.28346,{"lat":40,"lon":39},[43],{"name":44,"role":24,"phone":45,"phoneExt":20,"email":46},"Clinical Research Coordinator","+61 2 5124 4338","Ryshelle.kilby@act.gov.au",{"facility":48,"status":30,"city":49,"state":50,"zip":51,"country":34,"countryCode":35,"cosmosGeoPoint":52,"geoPoint":56,"contacts":57},"Liverpool Hospital","Sydney","New South Wales","2107",{"type":37,"coordinates":53},[54,55],151.20732,-33.86785,{"lat":55,"lon":54},[58],{"name":44,"role":24,"phone":59,"phoneExt":20,"email":60},"+61 474 279 274","pinky.patel@health.nsw.gov.au",{"facility":62,"status":30,"city":63,"state":64,"zip":65,"country":34,"countryCode":35,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Icon Cancer Center South Brisbane","Brisbane","Queensland","4066",{"type":37,"coordinates":67},[68,69],153.02809,-27.46794,{"lat":69,"lon":68},[72],{"name":44,"role":24,"phone":73,"phoneExt":20,"email":74},"+61 7 3737 4795","Annabelle.morton@icon.team",{"type":76,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100599397",false,"NCT07083960","OM336 in Autoimmune Cytopenias","An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants With Active Autoimmune Cytopenias","Key Inclusion Criteria:\n\n* Active autoimmune cytopenia\n* Relapsed\u002Frefractory after ≥1 prior treatment\n* Body weight ≥ 55 kg\n* Willing to comply with and study requirements and procedures\n\nKey Exclusion Criteria:\n\n* Previous treatment with a BCMA-targeted therapy\n* Clinically significant infection within 3 months of screening\n* Major surgery or splenectomy within 3 months of screening or planned during the study\n* Pregnant or breastfeeding","ALL","18 Years","75 Years",{"count":87,"type":88},32,"ESTIMATED","INTERVENTIONAL",[91],"PHASE1","An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.",[94,95,96],"AIHA - Warm Autoimmune Hemolytic Anemia","AIHA - Cold Autoimmune Hemolytic Anemia","ITP - Immune Thrombocytopenia","2025-09-24",{"date":99,"type":100},"2025-09-30","ACTUAL",{"date":102,"type":100},"2025-08-01",{"date":104,"type":88},"2027-09",{"name":5,"class":6},3]